Garry Menzel

Garry E.
Menzel currently works at Black Diamond Therapeutics, Inc., as Independent Director from 2017, Epilepsy Therapy Project, as Director, Adaptimmune Therapeutics Plc, as Independent Non-Executive Director from 2023, Roslin Cell Therapies Ltd., as Director from 2025, Epilepsy Foundation, as Member-National Board from 2003, Royal College of Art, as Principal, and GHO Capital Partners LLP, as Operating Partner from 2024.
Dr. Menzel also formerly worked at TCR² Therapeutics, Inc., as President, Chief Executive Officer & Director, Credit Suisse Group AG, as Managing Director in 2008, The Goldman Sachs Group, Inc., as Managing Director in 2004, Institute for Systems Biology, as Director, Stoke Therapeutics, Inc., as Independent Director from 2020 to 2026, DaVita, Inc., as Chief Financial Officer from 2013 to 2015, Regulus Therapeutics, Inc., as Chief Operating Officer from 2012 to 2013, Axcella Health, Inc., as Chief Strategy Officer from 2015 to 2016, Smithkline Beecham Plc, as Research Assistant from 2004 to 2008, and Bain & Co., Inc., as Consultant from 1994 to 2004.
Dr. Menzel received his undergraduate degree in 1985 from Imperial College London, doctorate degree in 1988 from the University of Cambridge, and Masters Business Admin degree in 1994 from Stanford Graduate School of Business.